Autologous Stem Cell Transplantation in Elderly Patients is Safe and is not associated with a Higher Frequency of Readmission Compared to Younger Patients. A Single Center Experience

Abstract

Seventy-two of 231 (31%) ASCT pts were > 65 yrs. Diagnosis was MM in 52 (72%) and NHL in 20 pts (28%) respectively. Median age was 69 (range 65-76). Patients’ comorbidities or significant laboratory abnormalities are summarized in (Table 1). Based on clinical judgement, conditioning regimen dose intensity was reduced in 10 pts (14%). In 12% (6/52) of MM pts melphalan dose was reduced to 140 mg/m2 (4) or 100 mg/m2 (2). FEAM dose was reduced at 75% in 4 NHL pts (20%) [1,2]. Pts achieved hematology recovery after a median of 10 days (6-13) and were discharged after 13 days (929). Infectious complications were the most frequent adverse event during the aplastic phase [3-5].